BPC-157

BPC-157 (also known as PL-14736, PLD-116, PL-10, or Bepecin) is a synthetic 15-amino acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and molecular weight of 1,419 Da. The compound was first described in 1992 and represents a partial sequence of body protection compound (BPC), an endogenous protein discovered in and isolated from human gastric juice. The peptide demonstrates remarkable chemical stability, remaining intact in human gastric acid for at least 24 hours—a property that distinguishes it from most peptides, which undergo rapid degradation in acidic environments.

BPC-157 was originally investigated in the early 1990s for its gastroprotective properties, demonstrating antiulcer effects comparable to H2 receptor antagonists (ranitidine, cimetidine) and protection against various gastrointestinal lesions induced by stress, cysteamine, and ethanol in animal models. Early research suggested the peptide had cytoprotective effects extending beyond the gastrointestinal tract to include the liver, pancreas, heart, nerves, bones, teeth, cornea, and endothelium.

Proposed Mechanisms of Action:

Angiogenesis: BPC-157 significantly promotes new blood vessel formation by enhancing vascular endothelial growth factor receptor-2 (VEGFR2) activity and upregulating VEGF protein and gene expression. This pathway is commonly implicated in wound healing and tissue repair, particularly in poorly vascularized tissues like tendons and ligaments.

Nitric Oxide Signaling: The peptide upregulates vasodilatory nitric oxide pathways, including upregulation of nitric oxide synthase (NOS) gene and protein expression and increased nitric oxide production through activation of the Akt-endothelial nitric oxide synthase (eNOS) pathway. This increases NO production, which is essential for endothelial proliferation, vessel dilation, and new capillary formation.

ERK1/2 Pathway Activation: BPC-157 upregulates the phosphorylation level of extracellular signal-regulated kinases (ERK) 1 and 2 as well as their downstream targets, including c-Fos, c-Jun, and Egr-1, which are key molecules involved in cell growth, migration, and angiogenesis.

FAK-Paxillin Signaling: In cultured tendon fibroblast models, BPC-157 was associated with increased FAK and paxillin gene expression, suggesting direct or indirect activation of the focal adhesion kinase (FAK)-paxillin pathway, important in cellular adhesion, migration, proliferation, and survival.

Growth Hormone Receptor: BPC-157 increased growth hormone receptor gene and protein expression in cultured rat tendon fibroblasts, identifying modulation of another proliferation-promoting pathway.

Anti-Inflammatory Effects: BPC-157 upregulates anti-inflammatory pathways and counteracts proinflammatory cytokines—it has been observed to decrease cyclooxygenase-2 (COX-2) gene expression, decrease myeloperoxidase activity, and decrease levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).  The peptide promotes resolution of inflammation by shifting macrophage activity from a pro-inflammatory (M1) phenotype toward a reparative (M2) phenotype, thereby reducing fibrosis and promoting enhanced tissue regeneration.²

Neurotransmitter Modulation: BPC-157 modulates dopamine and serotonin pathways, stabilizes acetylcholine receptors and nerve terminals at the neuromuscular junction, and normalizes disrupted neurotransmitter signaling involving dopamine, serotonin, and GABA.

Pharmacological Characteristics:

Very Short Half-Life: BPC-157 has a plasma half-life of less than 30 minutes following intravenous or intramuscular administration. Plasma concentrations return to baseline within 24 hours following single-dose administration.

Hepatic Metabolism: BPC-157 tissue concentration is highest in the kidneys, then the liver, with high concentrations found in bile, and extensive metabolism observed in in vitro human liver microsome models. The peptide is likely metabolized in the liver by cytochrome P450 enzymatic pathways and excreted in the urine.

Urinary Detection: BPC-157 metabolites are stable and detectable in urine for 4-5 days, with limits of detection ranging from 0.03 to 0.11 ng/mL using ultra-high-performance liquid chromatography mass spectrometry. These detection limits are below the minimum required levels (2 ng/mL) for peptide compounds set by WADA, providing analytical parameters suitable for use in athlete drug testing.

Sustained Biological Effects: While BPC-157’s pharmacokinetic half-life is very short (less than 30 minutes), the angiogenic, anti-inflammatory, and tissue regeneration processes it initiates appear to persist for weeks to months in animal studies, far exceeding the peptide’s pharmacokinetic presence. Animal data demonstrates that BPC-157’s therapeutic effects continue long after administration stops—for example, in spinal cord injury studies, functional improvements and reduced spasticity were maintained for up to 360 days after a single treatment. The sustained effects are thought to result from BPC-157’s activation of multiple gene expression pathways within minutes of administration, which then trigger cascading cellular processes that continue independently.² Essentially, the peptide acts as a biological “switch” that initiates self-sustaining healing programs rather than requiring continuous presence.

Routes of Administration: Preclinical studies employed intraperitoneal, intramuscular, intravenous, intragastric (oral), and local (direct tissue injection) administration routes. The three human studies used intraarticular (knee joint), intravesicular (bladder), and intravenous routes. Poor oral bioavailability is expected for most peptides, though BPC-157’s unusual gastric acid stability may confer some oral activity.

Regulatory and Legal Status:

FDA Classification: In September 2023, the FDA placed BPC-157 on the Category 2 Bulk Drug Substances List, meaning it “raises significant safety concerns.” The agency specifically cited risks of immunogenicity, peptide-related impurities, and lack of sufficient safety data for human use. This Category 2 designation effectively prohibits compounding pharmacies from using BPC-157 in compounded medications under FDA regulations.

WADA and Sports Organizations: In 2022, WADA specifically banned BPC-157 by name under the S0 Unapproved Substances category, prohibiting its use in both competition and training. Major professional and collegiate sports leagues followed suit, including the NFL, UFC, MLB, NCAA, NAIA, and PGA (Table 1).

Current Legal Status: BPC-157 is not a DEA scheduled substance, so possession is not illegal (unlike substances such as anabolic steroids). However, the FDA Category 2 designation prohibits its use in compounded medications. BPC-157 remains legally sold as “dietary supplements” or “research chemicals,” classifications that are not subject to FDA regulations for quality and safety. This creates a gray-area legal status where numerous medical clinics with licensed physicians across the United States offer treatment with this peptide, and it remains readily accessible for purchase online.

Unprecedented Public Interest: In June 2024, the “BPC-157” Google search volume index was at an all-time high. Concurrently, there are over 50 million “BPC-157” tagged video views on both YouTube and TikTok, with over 100,000 members in peptide-related Reddit communities.¹ These trends resemble another gray market class of drugs, selective androgen receptor modulators (SARMs), which also have minimal clinical safety data, similar widespread use, and recent regulatory bans, yet remain available in cash clinics and online.

BPC-157 operates through multiple interconnected molecular pathways that facilitate tissue healing and regeneration. The peptide’s pleiotropic effects span angiogenesis, inflammation, nitric oxide signaling, neurotransmitters, and tissue-specific repair mechanisms.

Molecular Mechanisms

VEGFR2 and Angiogenic Signaling:

BPC-157 significantly promotes angiogenesis by enhancing vascular endothelial growth factor receptor-2 (VEGFR2) activity and upregulating VEGF protein and gene expression. VEGFR2 activation triggers intracellular cascades involving increased NO production, essential for endothelial proliferation, vessel dilation, and new capillary formation, which may be particularly beneficial in ischemic or hypovascular musculoskeletal tissues. In rats with hind limb ischemia, BPC-157 both increased vessel density and accelerated blood flow recovery. The peptide also stabilizes existing vascular structures and modulates vascular tone via NO-mediated vasodilation, thereby safeguarding tissues against ischemic damage during repair processes.

Nitric Oxide (NO) Pathway Activation:

BPC-157 upregulates vasodilatory nitric oxide pathways primarily through activation of the Akt-endothelial nitric oxide synthase (eNOS) pathway, including upregulation of nitric oxide synthase (NOS) gene and protein expression and increased nitric oxide production.¹ ² Additionally, BPC-157 exerts cytoprotective effects by enhancing eNOS activity through Src kinase-caveolin-1 signaling, supporting cellular resilience by upregulating endogenous antioxidants, including heme oxygenase-1 (HO-1), thus reducing oxidative stress, preventing mitochondrial dysfunction, and limiting apoptosis.²

ERK1/2 Signaling Cascade:

BPC-157 activates the ERK1/2 (extracellular signal-regulated kinase) pathway as a key mechanism underlying its pro-healing and angiogenic properties.² In endothelial cell models, BPC-157 significantly enhances ERK1/2 phosphorylation in a dose-dependent manner, leading to increased cellular proliferation, migration, and vascular tube formation—processes central to tissue regeneration and angiogenesis.² These effects are mediated through downstream activation of transcription factors such as c-Fos, c-Jun, and EGR-1, which regulate genes involved in cell cycle progression, extracellular matrix remodeling, and angiogenic signaling.¹ ² When the ERK pathway is pharmacologically blocked, BPC-157’s pro-migratory and pro-angiogenic effects are abolished, underscoring the pathway’s critical role.²

FAK-Paxillin Pathway:

In cultured tendon fibroblasts isolated from rats, BPC-157 was associated with increased FAK and paxillin gene expression, suggesting direct or indirect activation of the focal adhesion kinase (FAK)-paxillin pathway, important in cellular adhesion, migration, proliferation, and survival.¹ ⁸ This mechanism contributes to BPC-157’s ability to enhance tendon fibroblast migration and cell survival under stress.⁸

Growth Hormone Receptor Modulation:

BPC-157 increased growth hormone receptor gene and protein expression in cultured tendon fibroblasts, identifying modulation of another proliferation-promoting pathway.¹ ⁸ This augments the anabolic healing response, improving tendon structure and biomechanical function.²

Anti-Inflammatory Modulation:

BPC-157 demonstrates pronounced anti-inflammatory properties by significantly decreasing pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon-gamma (IFN-γ).¹ ² The peptide decreases cyclooxygenase-2 (COX-2) gene expression and decreases myeloperoxidase activity.¹ It promotes resolution of inflammation by shifting macrophage activity from a pro-inflammatory (M1) phenotype toward a reparative (M2) phenotype, thereby effectively reducing fibrosis and promoting enhanced tissue regeneration.²

Neuromuscular Junction Stabilization:

BPC-157 preserves neuromuscular function by stabilizing acetylcholine receptors and nerve terminals at the neuromuscular junction (NMJ), effectively reversing paralysis induced by neuromuscular blockers such as succinylcholine and lidocaine in animal models.² It further maintains central nervous system homeostasis by normalizing disrupted neurotransmitter signaling involving dopamine, serotonin, and gamma-aminobutyric acid (GABA), essential for stabilizing synaptic function and ensuring neuromuscular coordination after injury or toxin exposure.² BPC-157 has also demonstrated the ability to normalize glutamatergic signaling, including in models of NMDA receptor overactivation, counteracting the neurotoxic effects of agents like ketamine and MK-801.²

Adrenergic System Modulation:

BPC-157 modulates the adrenaline and noradrenaline systems by counteracting both beta-adrenergic overstimulation (e.g., isoprenaline) and blockade (e.g., sotalol), preventing resultant hemodynamic collapse, multiorgan failure, and vascular occlusion-like syndromes in rodent models.²

Tissue-Specific Effects

Tendon and Ligament Healing:

BPC-157 accelerates tendon and ligament repair through enhanced fibroblast proliferation and collagen synthesis, primarily via focal adhesion kinase (FAK)-paxillin signaling pathways.² ⁸ It also increases growth hormone receptor (GHR) expression in fibroblasts, augmenting the anabolic healing response, thus improving tendon structure and biomechanical function, even in conditions impaired by corticosteroids or limited vascular supply.² In rat models with transected Achilles tendons, BPC-157 treatment improved functional and biomechanical indices, macroscopic and microscopic structures, increased load to failure, and resolved tendon-bone defects.¹ Studies demonstrated that BPC-157 not only improves tendon healing but also enhances tendon-to-bone integration, even in the presence of corticosteroids, which typically impair recovery.²

Muscle Regeneration:

In rodent models, BPC-157 significantly enhances myogenesis, muscle fiber regeneration, and functional recovery post-injury in skeletal muscle.² In 3 rat muscle transection and crush models, BPC-157 treatment improved muscle structure, function, and biomechanics, including improved load to failure, motor function indices, muscle myofibril and macroscopic diameters, and reduced atrophy and subcutaneous gapping.¹ By facilitating rapid re-establishment of myotendinous junctions and reducing fibrosis at injury sites, BPC-157 improves overall muscular integrity and contractile function, crucial for recovery from severe muscular trauma or degenerative muscular conditions.²

Ligament Healing:

In 1 rat medial collateral ligament (MCL) transection model, BPC-157 treatment reduced postinjury valgus instability and contracture, and restored biomechanics (MCL load to failure, stiffness, breaking force, and absorbed energy indices), motor function indices, and macroscopic and microscopic structure.¹

Bone Healing:

BPC-157 promotes osteogenesis and accelerates bone healing, particularly under compromised conditions such as delayed union, avascular osteonecrosis, or impaired fracture healing.² In rabbit nonunion models, intramuscular administration of BPC-157 performed similarly to percutaneous injection of autologous bone marrow or autologous bone grafting in improving callous mineralization and resolution of the bone defect with predominantly lamellar bone formation versus fibrous scar tissue.¹ By stimulating angiogenesis within bone tissue and enhancing osteoblast activity via VEGFR2-NO signaling, BPC-157 markedly improves bone matrix deposition and fracture consolidation.²

Endothelial and Vascular Effects:

In vitro, BPC-157 improved tendon fibroblast survival under stress, cell migration indices, cell proliferation, and growth hormone receptor expression.¹ Histologic analysis of transected rat muscle and tendon models demonstrated decreased inflammatory infiltrates following BPC-157 treatment, and BPC-157 increased local vascularity and VEGF expression in muscle, tendon, and ligament injury models.¹

Anti-Inflammatory Effects in Arthritis:

In Freund’s adjuvant–induced polyarthritis rat models, BPC-157 reduced paw inflammation, nodule formation, and stiffness.¹

Sustained Biological Effects Beyond Pharmacokinetics:

While BPC-157 has a very short half-life (less than 30 minutes), the angiogenic, anti-inflammatory, and tissue regeneration processes it initiates appear to persist for weeks to months in animal studies, far exceeding the peptide’s pharmacokinetic presence.² Animal data demonstrates that BPC-157’s therapeutic effects continue long after administration stops: in spinal cord injury studies, functional improvements and reduced spasticity were maintained for up to 360 days after a single treatment, while in one tendon healing study, biomechanical improvements persisted through the 21–72 day observation period.² The sustained effects are thought to result from BPC-157’s activation of multiple gene expression pathways within minutes of administration (including genes like Akt1, VEGFR2, eNOS, and numerous growth factors), which then trigger cascading cellular processes that continue independently.² Essentially, the peptide acts as a biological “switch” that initiates self-sustaining healing programs rather than requiring continuous presence.²

Comprehensive Systematic Reviews

Design: PRISMA-compliant systematic review examining BPC-157’s mechanism of action, musculoskeletal effects, metabolism, and safety profile from database inception to June 3, 2024.¹

Methodology:

• Comprehensive search of PubMed, Cochrane, and Embase databases
• 544 articles initially identified from 1993 to 2024
• Two independent reviewers screened articles in 3 phases
• Included studies reporting BPC-157’s mechanism, musculoskeletal outcomes, metabolism, and safety
• Discrepancies resolved by group consensus

Results:

• Total studies included: 36 studies (35 preclinical animal studies, 1 clinical human study)
• Publication timeframe: 1993 to 2024
• Evidence level: Level IV and Level V studies only

Key Findings:

Mechanism of Action (21 studies): BPC-157 enhances growth hormone receptor expression and activates multiple pathways involved in cell growth and angiogenesis (VEGFR2, ERK1/2, FAK-paxillin, Akt-eNOS), while reducing inflammatory cytokines (IL-6, TNF-α, COX-2).

Musculoskeletal Outcomes (14 preclinical studies): In preclinical models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries. Outcomes included increased load to failure, improved motor function indices, enhanced tissue structure, reduced inflammatory infiltrates, increased vascularity, and accelerated healing even in corticosteroid-impaired models.

Human Clinical Data (1 study): Retrospective study of 12 patients with unspecified chronic knee pain who received intraarticular injection of BPC-157 (2 cc of 2000 mcg/mL solution): 7 of 12 patients (58%) reported subjective relief for >6 months.

Metabolism (3 studies): BPC-157 is metabolized in the liver with a half-life of less than 30 minutes. It is cleared by the kidneys and excreted in the urine. BPC-157 metabolites are stable and detectable in urine for 4 days with a limit of detection of 0.1 ng/mL using high-resolution liquid chromatography mass spectrometry.

Safety Profile (3 preclinical studies): Preclinical safety studies showed no adverse effects across several organ systems (liver, spleen, lung, kidney, brain, thymus, prostate, ovaries) following single and repeat doses ranging from 6 μg/kg to 20 mg/kg over 6 weeks in rat and dog models. No toxic or lethal dose was identified. BPC-157 demonstrated no in vitro mutagenic or genotoxic effects and no in vivo teratogenicity at studied doses.

**Critical Limitation – No Human Safety Data:**¹

“No study assessed the safety or adverse events of BPC-157 in humans.”

Conclusions:

“This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries. Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety. We recommend that clinicians counsel athletes to understand their organizations’ rules to remain compliant with medication/supplement safety and testing standards.”

“These outcome measures have not been clinically studied in humans, yet a Google search reveals that licensed medical practitioners, including orthopedic and sports medicine specialists, are offering BPC-157 treatment for musculoskeletal injuries. In fact, there was only 1 registered clinical trial (phase I) with an unknown status since 2016. This highlights an important gap in the BPC-157 musculoskeletal literature for future multidisciplinary clinical investigation.”

“BPC-157 modulates cell growth, proliferation, survival, anti-inflammatory, and angiogenesis pathways. While no acute adverse events (<6 weeks) were reported in preclinical animal models, clinical safety in humans remains unknown. Due to limited high-quality clinical evidence, clinicians and athletes should exercise caution when considering the use of BPC-157.”

Design: Narrative scoping review examining molecular mechanisms, therapeutic potential, and safety concerns of BPC-157 in musculoskeletal healing, published through March 2025.²

Methodology:

• Structured literature search of six electronic databases (PubMed, Embase, CINAHL Complete, SportDiscus, BIOSIS Citation Index, Web of Science Core Collection)
• Search strategies incorporated combinations of keywords and subject headings including “BPC-157,” “PLD-116,” “PL-10,” “PL 14736,” and “body protective compound”
• Three reviewers independently screened titles and abstracts
• Filters applied to limit to English-language, peer-reviewed publications
• Discrepancies resolved by consensus

Key Findings:

Molecular Pathways: “BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects.”

Tissue-Specific Effects: BPC-157 accelerates tendon and ligament repair through enhanced fibroblast proliferation and collagen synthesis via FAK-paxillin pathways. It enhances myogenesis and muscle fiber regeneration. It promotes osteogenesis and accelerates bone healing, particularly under compromised conditions. It activates ERK1/2 pathways critical for endothelial proliferation, migration, and angiogenesis.

Sustained Effects: “While BPC-157 is noted to have a very short half-life (less than 30 min), the angiogenic, anti-inflammatory, and tissue regeneration processes it initiates appear to persist for weeks to months in animal studies, far exceeding the peptide’s pharmacokinetic presence. Animal data demonstrates that BPC-157’s therapeutic effects continue long after administration stops: for example, in spinal cord injury studies, functional improvements and reduced spasticity were maintained for up to 360 days after a single treatment.”

Human Data Summary: “Unfortunately, there have been limited in vivo clinical trials conducted to demonstrate the effectiveness of BPC-157 usage in humans. To our knowledge, there have only been three published studies.”

Human Studies Identified:

1. Lee & Padgett 2021: Retrospective study of 16 patients contacted to review knee pain improvements 6 months to 1 year after receiving intraarticular knee injections with BPC-157 or BPC-157 plus thymosin-beta-4. “In total, 14 of the 16 patients had significant pain relief when given an intraarticular knee injection with BPC-157 or BPC-157 plus TB4. While this study had many limitations (e.g. small sample size, lack of control group, lack of common diagnosis), it did demonstrate improved pain in 87.5% of patients who received injections containing BPC-157.”
2. Lee et al. 2024: Pilot study of 12 individuals with moderate to severe interstitial cystitis receiving intravesicular (bladder) injections of BPC-157 (10 mg): “All 12 patients reported significant improvement in symptoms” at 6 weeks post-treatment with 80–100% resolution. “There were no reported side effects after intravesicular BPC-157 administration. Specifically, the participants were screened for fevers, skin rash, nausea, vomiting, worsening urinary symptoms and dyspareunia. Additionally, 0 of 12 participants experienced any hematuria or acute cystitis following treatment.”
3. Lee & Burgess 2025: Pilot study involving two healthy adults who received intravenous BPC-157 infusions up to 20 mg. “The treatment was well tolerated, with no adverse events or clinically meaningful changes observed in vital signs, electrocardiograms, or laboratory biomarkers assessing cardiac, hepatic, renal, thyroid, or metabolic function. Pharmacokinetic analysis showed that plasma BPC-157 concentrations returned to baseline within 24 h, consistent with its known rapid clearance and short half-life.”

Safety Discussion: “Due to the paucity of studies done in humans thus far, there is also limited data regarding safety and associated side effects. In the three human studies completed, the safety profile has been promising.”

However, the review discusses proposed theoretical side effects based on in vitro effects: “Proposed side effects have been discussed based on the in vitro effects of BPC-157. These possible unwanted effects include pathologic angiogenesis, toxic metabolite formation, and overproduction of nitric oxide.”

Pathologic Angiogenesis Concerns: “Pathologic angiogenesis is implicated in the proliferation of tumor cells, as well as in immune and inflammatory disease processes. Angiogenesis occurs with contribution from VEGF and its receptors, eNOS and EGR-1, all of which have been shown to be affected and upregulated by BPC-157.” However, the review notes: “Contrary to the tumor-promoting potential of many angiogenic agents, BPC-157 has been shown to inhibit uncontrolled cell proliferation, downregulate VEGF expression, and counteract VEGF-driven tumorigenesis, including suppression of Ki-67 and VEGF pathway activation.”

Preclinical Safety Data: “Although the proposed adverse effects discussed above deserve scrutiny, a pre-clinical safety evaluation by Xu et al. (2020) found BPC-157 to be well tolerated at high doses in animal models. The researchers were unable to identify a minimum toxic dose or a lethal dose and reported no teratogenic, genotoxic, anaphylactic, or local toxic effects. These findings support the rationale for initiating formal human clinical trials.”

Conclusions:

“BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.”

“However, despite this promise, and growing interest in athletic and online communities, human data is exceedingly sparse. The absence of high-quality trials in humans limits the ability to assess its human safety, efficacy, and appropriate clinical use. Furthermore, all the published studies report positive or beneficial effects of BPC-157, suggesting a possible publication bias toward positive findings, thus raising questions about the robustness and reproducibility of the reported benefits.”

“This lack of human evidence has led both the FDA and WADA to restrict BPC-157, citing concerns about unregulated use, unknown human toxicity profiles, and potential for misuse. Its continued availability via ‘research chemical’ websites and the growing presence of anecdotal promotion on social media only heighten the urgency for rigorous scientific investigation. Until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use in musculoskeletal medicine.”

The Missing Phase I Trial

Both systematic reviews and additional sources identify a critical gap in human safety data: a registered Phase I clinical trial that was completed but never published.

Unpublished Phase I Trial (2015-2016):

• Study Population: 42 healthy volunteers
• Design: Phase I trial to assess BPC-157’s safety and pharmacokinetics
• Status: Trial initiated in 2015, marked as “completed” in 2016
• Critical Issue: “The researchers cancelled submission of the results” and never published findings¹⁰

This represents a major evidence gap—the only formal Phase I safety trial in healthy volunteers was conducted, completed, but its results were suppressed.¹⁰ The reasons for cancelling submission of the results remain unknown, raising significant questions about what the trial found.¹⁰

Key Preclinical Studies

Design: In vitro and ex vivo study examining BPC-157’s effects on cultured rat Achilles tendon explants and fibroblasts.

Study Components:

• Tendon explant outgrowth assay
• Cell migration transwell filter experiments
• Cell survival under oxidative stress (H₂O₂ exposure)
• FAK-paxillin pathway analysis

Results:

• BPC-157 accelerated initial outgrowth of tendon fibroblasts from tendon explants, designed to mimic the very early stage of tendon regeneration
• Tendon cells with 24 h treatment with BPC-157 significantly increased their migratory speed up to 2.3-fold at the concentration of 2 μg/mL
• BPC-157 enhanced cell survival under oxidative stress
• BPC-157 activated the FAK-paxillin pathway, important in cellular adhesion, migration, proliferation, and survival

Significance: This study was designed to investigate the potential mechanism of BPC-157 to enhance healing of injured tendon, providing mechanistic insights into how the peptide promotes tendon repair at the cellular level.⁸

Staresinic M et al., 2003 – Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon

Design: Rat Achilles tendon transection model examining BPC-157’s effects on functional and biomechanical healing.¹

Results:

• Improved Achilles tendon structural, functional, and biomechanical indices
• Reduced inflammatory infiltrates
• Enhanced tendon healing outcomes

Cerovecki T et al., 2010 –

Design: Rat medial collateral ligament (MCL) transection model examining BPC-157 effects at 90 days post-transection.¹

Results:

• Reduced postinjury valgus instability and contracture
• Restored motor function indices
• Improved MCL biomechanical indices (load to failure, stiffness, breaking force, absorbed energy)
• Restored macroscopic and microscopic structures

Early Inflammatory Bowel Disease Research

Sikiric P et al., 2013 –

Context: BPC-157 was in clinical trials as a therapy for inflammatory bowel disease (IBD) under the designation PL14736.⁵ ⁷

**Preclinical IBD Research:**⁵ ⁷

• BPC-157 demonstrated effectiveness in healing colocutaneous fistulas in rat models
• Effective against cysteamine-induced colitis models
• Administered per-orally (orally) as an anti-ulcer peptide, stable in human gastric juice
• Doses: 10 µg/kg, 10 ng/kg administered intraperitoneally once daily or per-orally in drinking water (0.16 µg/ml/12 ml/day)

*Results:*⁵ ⁷

• BPC-157 animals exhibited less colitis lesions and advanced anastomosis healing
• Functioned much better and mostly achieved pre-operative weight
• Effective via both intraperitoneal and oral routes

Sikiric P et al., 2011

Summary: “BPC 157 (GEPPPGKPADDAGLV, MW 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect.”⁷

Critical Note: Despite references to “clinical phase II” trials for inflammatory bowel disease in the early 2000s-2010s, neither systematic review identified any published controlled clinical trial results for BPC-157 in IBD or any other condition.¹ ² The Croatian research group that developed BPC-157 referenced clinical trials in progress but published results have never appeared in peer-reviewed literature.

Regulatory Status

As of January 2026, BPC-157 occupies a uniquely problematic regulatory position:

**FDA Category 2 Designation (September 2023):**³ ⁴

The FDA placed BPC-157 on the Category 2 Bulk Drug Substances List, meaning it “raises significant safety concerns.”³ The agency specifically cited:³ ⁴

• Risk of immunogenicity for certain routes of administration
• Complexities with peptide-related impurities
• Challenges with active pharmaceutical ingredient (API) characterization
• Lack of sufficient safety data for human use

This Category 2 designation effectively prohibits compounding pharmacies from using BPC-157 in compounded medications under FDA regulations.³ ⁴

**WADA and Sports Bans (2022):**¹ ⁹

WADA specifically banned BPC-157 by name in 2022 under the S0 Unapproved Substances category, prohibiting its use in both competition and training.¹ ⁹ Major professional sports leagues followed suit, including the NFL, UFC, MLB, NCAA, NAIA, and PGA.¹

**Never FDA-Approved:**¹ ²

BPC-157 has never been FDA-approved for any indication and is not approved in any surveyed country.¹ ² All current use occurs outside regulatory oversight.

**Continued Availability Despite Restrictions:**¹

Despite FDA and WADA restrictions, BPC-157 remains widely available through:¹

• “Research chemical” suppliers (not subject to FDA regulations)
• “Dietary supplement” classifications (not subject to FDA drug regulations)
• Cash-based medical clinics operated by licensed physicians
• Direct-to-consumer online sales

Because BPC-157 is not a DEA scheduled substance, possession is not illegal.¹ This creates a gray-area legal status where the compound remains readily accessible despite regulatory concerns.¹

Research Evidence Summary

**Preclinical Evidence (35 animal studies):**¹ ²

The preclinical evidence base for BPC-157 is substantial, with over 35 animal studies demonstrating:¹ ²

• Accelerated healing of tendons, ligaments, muscles, and bones
• Enhanced angiogenesis and tissue vascularization
• Reduced inflammatory markers
• Improved biomechanical outcomes (load to failure, tissue strength)
• Functional recovery improvements
• No acute toxicity across multiple organ systems at doses from 6 μg/kg to 20 mg/kg over 6 weeks
• No mutagenic, genotoxic, or teratogenic effects in preclinical models

**Human Evidence (3 small studies, N=30 total subjects):**¹ ²

1. Lee & Padgett 2021: Retrospective case series, 12 knee pain patients, 7 of 12 (58%) reported relief >6 months
2. Lee et al. 2024: Pilot study, 12 interstitial cystitis patients, all 12 reported improvement, no adverse events
3. Lee & Burgess 2025: Pharmacokinetic pilot, 2 healthy volunteers, well tolerated, no adverse events

**Critical Evidence Gaps:**¹ ²

• No randomized controlled trials in any population for any indication
• No adequately powered efficacy trials in humans
• No long-term safety data beyond 6 weeks (animal) or 6 months (retrospective human)
• Unpublished Phase I trial: Completed in 2016 with 42 healthy volunteers but “cancelled submission of the results”—never published¹⁰
• No peer-reviewed clinical trial results despite references to “clinical phase II” trials in Croatia⁷
• Publication bias concern: All published studies report positive or beneficial effects, “suggesting a possible publication bias toward positive findings, thus raising questions about the robustness and reproducibility of the reported benefits”²

Theoretical Safety Concerns

Both systematic reviews discuss theoretical safety concerns based on BPC-157’s mechanisms of action:² ¹⁰

**Pathologic Angiogenesis:**²

“Pathologic angiogenesis is implicated in the proliferation of tumor cells, as well as in immune and inflammatory disease processes. Angiogenesis occurs with contribution from VEGF and its receptors, eNOS and EGR-1, all of which have been shown to be affected and upregulated by BPC-157.”²

However, the review notes countervailing evidence: “Contrary to the tumor-promoting potential of many angiogenic agents, BPC-157 has been shown to inhibit uncontrolled cell proliferation, downregulate VEGF expression, and counteract VEGF-driven tumorigenesis, including suppression of Ki-67 and VEGF pathway activation.”²

**Toxic Metabolite Formation:**²

“One of the primary metabolites of BPC-157 is thought to be Proline, which has been shown to play a role in superoxide production and intracellular cascades whose downstream effects could interfere with a variety of biomolecules leading to widespread pathologic effects.”²

**Nitric Oxide Overproduction:**²

“BPC-157 robustly stimulates the NO system, which, at high levels, inhibits heme insertion into hemoglobin and alters the activity of heme thiolate enzymes and CYP enzymes. These effects are associated with the development of anemia and altered drug metabolism. Additionally, upregulation of NO has also been implicated in the development of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.”²

**Anecdotal Online Reports:**¹

“It is important to acknowledge that many anonymous online users of BPC-157 report adverse effects, including injection site pain and swelling, joint pain, anxiety, panic attacks, heart palpitations, insomnia, drowsiness, weakness, fatigue, loss of appetite, depression, and anhedonia. These side effects could be possible in the setting of unregulated production, contamination, and/or the ability of BPC-157 to modulate inflammatory, dopamine, and serotonin pathways.”¹

**FDA Safety Concerns (Category 2 Designation):**³ ⁴

The FDA’s specific safety concerns include:

• Immunogenicity: Risk of immune reactions for certain routes of administration
• Peptide-related impurities: Quality control challenges with unregulated manufacturing
• API characterization: Difficulty ensuring consistent active ingredient quality

Unregulated Manufacturing Risks

**Product Quality Concerns:**¹

“Without an FDA-approved indication, BPC-157 remains an unregulated supplement, and anywhere between 12% and 58% of ergo-nutritional supplements are contaminated with other, oftentimes unsafe, substances.”¹

“Any products marketed as BPC-157 are unregulated for quality and safety.”¹

“Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety.”¹

Expert Consensus

Both 2025 systematic reviews reached similar conclusions:

**Vasireddi et al. (Case Western / University Hospitals Cleveland):**¹

“This systematic review suggests that BPC-157 has the potential to reduce inflammation, promote vascularity, and augment structural, biomechanical, and functional recovery in fracture, muscle, tendon, and ligamentous injury models.”

“While no acute adverse events (<6 weeks) were reported in preclinical animal models, clinical safety in humans remains unknown.”

“Due to limited high-quality clinical evidence, clinicians and athletes should exercise caution when considering the use of BPC-157.”

“These outcome measures have not been clinically studied in humans, yet a Google search reveals that licensed medical practitioners, including orthopedic and sports medicine specialists, are offering BPC-157 treatment for musculoskeletal injuries. In fact, there was only 1 registered clinical trial (phase I) with an unknown status since 2016. This highlights an important gap in the BPC-157 musculoskeletal literature for future multidisciplinary clinical investigation.”

**McGuire et al. (University of Utah):**²

“BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine.”

“Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available.”

“Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution.”

“This lack of human evidence has led both the FDA and WADA to restrict BPC-157, citing concerns about unregulated use, unknown human toxicity profiles, and potential for misuse.”

“Until well-designed human trials are conducted and published, BPC-157 should not be recommended for clinical use in musculoskeletal medicine.“

“All the published studies report positive or beneficial effects of BPC-157, suggesting a possible publication bias toward positive findings, thus raising questions about the robustness and reproducibility of the reported benefits.”

Important Considerations

Promising Preclinical Evidence ≠ Human Efficacy: Over 35 animal studies demonstrate consistent beneficial effects across multiple injury models.¹ ² However, many promising preclinical compounds fail to translate to human efficacy and safety.² The absence of controlled human trials means the actual clinical utility remains speculative.

Three Human Studies, All Open-Label: The only three human studies (N=30 total subjects) were all uncontrolled, open-label designs without placebo comparisons.¹ ² While short-term tolerance appeared favorable, these studies cannot establish efficacy or detect uncommon adverse events.

The Missing Phase I Trial: A formal Phase I trial with 42 healthy volunteers was completed in 2016 but the researchers “cancelled submission of the results” and never published.¹⁰ This represents the most significant safety study conducted in humans, yet its findings remain unknown—raising serious questions about what was discovered.

FDA Category 2 = “Significant Safety Concerns”: The FDA’s 2023 designation explicitly cites “significant safety concerns” including immunogenicity, impurities, and insufficient human safety data.³ ⁴ This is not a regulatory technicality—it reflects substantive concerns about human use.

WADA Ban Reflects Performance Enhancement Concerns: WADA’s specific ban by name (not just as an unapproved substance) suggests the agency views BPC-157 as having performance-enhancing potential meriting targeted prohibition.¹ ⁹

Unregulated Product Quality: Without FDA oversight, products sold as “BPC-157” have no quality assurance.¹ Studies show 12-58% of ergogenic supplements contain contaminants or unlisted substances.¹ Reported adverse effects may result from contamination rather than BPC-157 itself.¹

Theoretical vs. Observed Safety: Theoretical safety concerns (pathologic angiogenesis, toxic metabolites, NO overproduction) are based on mechanism, not observed human harms.² However, the lack of long-term human data means these concerns cannot be dismissed.²

Publication Bias: “All the published studies report positive or beneficial effects of BPC-157, suggesting a possible publication bias toward positive findings.”² The absence of neutral or negative findings raises questions about selective reporting.²

Croatian Clinical Trials – Unpublished: Multiple publications from the Croatian research group that discovered BPC-157 reference “clinical trials” and “clinical phase II” for inflammatory bowel disease (PL14736).⁵ ⁷ However, neither 2025 systematic review identified any published controlled clinical trial results.¹ ² This disconnect—references to trials without published results—mirrors the missing Phase I trial.

Unprecedented Public Interest Without Evidence: June 2024 saw all-time high Google search volumes for BPC-157, with over 50 million tagged videos on YouTube and TikTok.¹ This massive public interest is driven by anecdotal reports and preclinical data, not clinical evidence.¹

Athlete Use Widespread Despite Bans: Athletes are using BPC-157 for injury recovery and performance enhancement despite explicit bans by WADA and major sports leagues.¹ The short urinary detection window (4-5 days) poses challenges for doping control.¹

Medical Clinics Offering Treatment: Licensed medical practitioners, including orthopedic and sports medicine specialists, are offering BPC-157 treatment for musculoskeletal injuries through cash-based clinics.¹ This practice occurs entirely outside evidence-based medicine.¹

Dosing Based on Preclinical Models: Preclinical studies used doses ranging from 6 μg/kg to 20 mg/kg.¹ Human studies used fixed doses (2000-10000 mcg per injection, 20 mg IV).¹ ² No dose-finding studies have established optimal human dosing for any indication.

Short-Term vs. Long-Term Safety: Preclinical studies assessed acute effects (<6 weeks).¹ Human studies reported outcomes at 6 weeks to 6 months.¹ ² No data exist on long-term safety beyond 6 months, and no data exist on chronic use over years.

Mechanism Complexity: BPC-157 modulates numerous pathways (VEGFR2, eNOS, ERK1/2, FAK-paxillin, GH receptor, neurotransmitter systems).¹ ² This pleiotropic activity makes predicting human effects difficult and raises concerns about unintended consequences in complex biological systems.

Sustained Effects Beyond Half-Life: The paradox of very short pharmacokinetic half-life (<30 min) yet sustained biological effects (weeks to months, up to 360 days in one study) suggests BPC-157 triggers self-sustaining cascades.² While potentially beneficial for healing, this also means effects cannot be quickly reversed if problems emerge.²

Regulatory Gray Zone: BPC-157 is not illegal to possess (not DEA scheduled), not approved by FDA (never underwent approval process), banned for compounding (Category 2), banned in sports (WADA), yet legally sold as “research chemical” or “dietary supplement.”¹ ³ ⁴ This creates confusion about legality and legitimacy.

Alternative Approaches Exist: For musculoskeletal injuries, evidence-based treatments include:

• Physical therapy and rehabilitation: Strong evidence for efficacy
• PRP (platelet-rich plasma): Some evidence in select conditions
• Corticosteroid injections: Evidence for short-term symptom relief (though may impair healing)
• Surgical repair: Evidence-based for specific structural injuries
• Time and appropriate loading: Natural healing processes with proven track record

None require using an FDA Category 2 substance with minimal human data.

Research Need is Urgent: Both systematic reviews conclude that given the robust preclinical evidence and massive public interest, there is an urgent need for well-designed human clinical trials to establish safety, efficacy, and appropriate clinical use.¹ ² Until such trials are conducted and published, use should be considered.